Richard We Clarkson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard We Clarkson has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Matthew John Smalley
The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, UK
18 shared publications Arthi A. Macpherson
16 shared publications- Carleen Cullinane
Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
16 shared publications Christina M. Fennell
16 shared publications- Helen B. Pearson
The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK
16 shared publications - Jason Li
Peter MacCallum Cancer Centre
16 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 12, 100702
Multi-site validation of an AI-based biomarker test for determining ER, PR, and HER2 status from H&E-stained breast cancer slides
- 14 April 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 12, 100702
Open AccessMulti-site validation of an AI-based biomarker test for determining ER, PR, and HER2 status from H&E-stained breast cancer slides
- Open Access
- 10 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 143
Suppression of Bcl3 Disrupts Viability of Breast Cancer Cells through Both p53-Dependent and p53-Independent Mechanisms via Loss of NF-κB Signalling
The NF-κB co-factor Bcl3 is a proto-oncogene that promotes breast cancer proliferation, metastasis and therapeutic resistance, yet its role in breast cancer cell survival is unclear. Here, we sought to determine the effect of Bcl3 suppression alone on breast cancer cell viability, with a view to informing future studies that aim to target Bcl3 therapeutically. Bcl3 was suppressed by siRNA in breast cancer cell lines before changes in viability, proliferation, apoptosis and senescence were examined. Bcl3 suppression significantly reduced viability and was shown to induce apoptosis in all cell lines tested, while an additional p53-dependent senescence and senescence-associated secretory phenotype was also observed in those cells with functional p53. The role of the Bcl3/NF-κB axis in this senescence response was confirmed via siRNA of the non-canonical NF-κB subunit NFKB2/p52, which resulted in increased cellular senescence and the canonical subunit NFKB1/p50, which induced the senescence-associated secretory phenotype. An analysis of clinical data showed a correlation between reduced relapse-free survival in patients that expressed high levels of Bcl3 and carried a p53 mutation. Together, these data demonstrate a dual role for Bcl3/NF-κB in the maintenance of breast cancer cell viability and suggests that targeting Bcl3 may be more beneficial to patients with tumours that lack functional p53.
- 10 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 143
Open AccessSuppression of Bcl3 Disrupts Viability of Breast Cancer Cells through Both p53-Dependent and p53-Independent Mechanisms via Loss of NF-κB Signalling
The NF-κB co-factor Bcl3 is a proto-oncogene that promotes breast cancer proliferation, metastasis and therapeutic resistance, yet its role in breast cancer cell survival is unclear. Here, we sought to determine the effect of Bcl3 suppression alone on breast cancer cell viability, with a view to informing future studies that aim to target Bcl3 therapeutically. Bcl3 was suppressed by siRNA in breast cancer cell lines before changes in viability, proliferation, apoptosis and senescence were examined. Bcl3 suppression significantly reduced viability and was shown to induce apoptosis in all cell lines tested, while an additional p53-dependent senescence and senescence-associated secretory phenotype was also observed in those cells with functional p53. The role of the Bcl3/NF-κB axis in this senescence response was confirmed via siRNA of the non-canonical NF-κB subunit NFKB2/p52, which resulted in increased cellular senescence and the canonical subunit NFKB1/p50, which induced the senescence-associated secretory phenotype. An analysis of clinical data showed a correlation between reduced relapse-free survival in patients that expressed high levels of Bcl3 and carried a p53 mutation. Together, these data demonstrate a dual role for Bcl3/NF-κB in the maintenance of breast cancer cell viability and suggests that targeting Bcl3 may be more beneficial to patients with tumours that lack functional p53.
- Open Access
- 9 January 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-17
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age
In the early 1990’s a group of unrelated genes were identified from the sites of recurring translocations in B-cell lymphomas. Despite sharing the nomenclature ‘Bcl’, and an association with blood-borne cancer, these genes have unrelated functions. Of these genes, BCL2 is best known as a key cancer target involved in the regulation of caspases and other cell viability mechanisms. BCL3 on the other hand was originally identified as a non-canonical regulator of NF-kB transcription factor pathways – a signaling mechanism associated with important cell outcomes including many of the hallmarks of cancer. Most of the early investigations into BCL3 function have since focused on its role in NF-kB mediated cell proliferation, inflammation/immunity and cancer. However, recent evidence is coming to light that this protein directly interacts with and modulates a number of other signaling pathways including DNA damage repair, WNT/β-catenin, AKT, TGFβ/SMAD3 and STAT3 – all of which have key roles in cancer development, metastatic progression and treatment of solid tumours. Here we review the direct evidence demonstrating BCL3’s central role in a transcriptional network of signaling pathways that modulate cancer biology and treatment response in a range of solid tumour types and propose common mechanisms of action of BCL3 which may be exploited in the future to target its oncogenic effects for patient benefit.
- 9 January 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-17
Open AccessMultifaceted roles for BCL3 in cancer: a proto-oncogene comes of age
In the early 1990’s a group of unrelated genes were identified from the sites of recurring translocations in B-cell lymphomas. Despite sharing the nomenclature ‘Bcl’, and an association with blood-borne cancer, these genes have unrelated functions. Of these genes, BCL2 is best known as a key cancer target involved in the regulation of caspases and other cell viability mechanisms. BCL3 on the other hand was originally identified as a non-canonical regulator of NF-kB transcription factor pathways – a signaling mechanism associated with important cell outcomes including many of the hallmarks of cancer. Most of the early investigations into BCL3 function have since focused on its role in NF-kB mediated cell proliferation, inflammation/immunity and cancer. However, recent evidence is coming to light that this protein directly interacts with and modulates a number of other signaling pathways including DNA damage repair, WNT/β-catenin, AKT, TGFβ/SMAD3 and STAT3 – all of which have key roles in cancer development, metastatic progression and treatment of solid tumours. Here we review the direct evidence demonstrating BCL3’s central role in a transcriptional network of signaling pathways that modulate cancer biology and treatment response in a range of solid tumour types and propose common mechanisms of action of BCL3 which may be exploited in the future to target its oncogenic effects for patient benefit.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 1: PIK3CA mutations are predominantly missense mutations and PTEN mutation/loss predicts for poor prostate cancer patient survival. (A) Pie chart depicting the frequency of missense/nonsense mutations, in-frame deletions and fusion events in PIK3CA identified in the 9 prostate cancer genomic datasets assessed in Fig. 1A (3-10). (B) Kaplan-Meier plot comparing TCGA provisional prostate adenocarcinoma dataset with PTEN homozygous deletion, loss or mutation compared to the general population. PTEN age-adjusted COXPH HR: 0.47, P = 0.0026* (n = 492, samples with sequencing and CNA data only). Data was obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/). PTEN copy number loss criteria; Log R ratio {less than or equal to} -0.48, probe number {greater than or equal to} 10. Silent mutations were excluded.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 1: PIK3CA mutations are predominantly missense mutations and PTEN mutation/loss predicts for poor prostate cancer patient survival. (A) Pie chart depicting the frequency of missense/nonsense mutations, in-frame deletions and fusion events in PIK3CA identified in the 9 prostate cancer genomic datasets assessed in Fig. 1A (3-10). (B) Kaplan-Meier plot comparing TCGA provisional prostate adenocarcinoma dataset with PTEN homozygous deletion, loss or mutation compared to the general population. PTEN age-adjusted COXPH HR: 0.47, P = 0.0026* (n = 492, samples with sequencing and CNA data only). Data was obtained from the TCGA data portal (https://tcga-data.nci.nih.gov/). PTEN copy number loss criteria; Log R ratio {less than or equal to} -0.48, probe number {greater than or equal to} 10. Silent mutations were excluded.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 3: Characterization of Pik3ca-mutated and Pten-deleted prostate hyperplasia and carcinoma. (A) IHC to detect the apoptotic marker Cleaved-Caspase-3 (CC3) in Wt, Pik3ca+/HR and Ptenfl/fl mice at 400 d (scale bar: 50 um). (B) Quantitation of CC3-positive nuclei in Wt, Pik3ca+/HR and Ptenfl/fl prostate epithelium (n = 3, *P <0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey's multiple comparison test, ns = not significant. Error bars: SEM). (C) IHC to detect CK5 and CK8 in Pik3ca+/HR and Ptenfl/fl carcinomas (representative images from 3 prostates per genotype, scale bar: 50 um). (D) Representative IHC images to detect PTEN, mTORC1 signaling components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 Thr37/46) and mTORC2 substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Pik3ca+/HR and Ptenfl/fl hyperplastic lesions (n = 3, scale bar: 50 um). IHC quantitation for (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca+/HR and Ptenfl/fl prostate hyperplastic lesions (n = 3, Error bars: SEM, *P < 0.05, unpaired, two-tailed t-test).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Supplementary Figure 3: Characterization of Pik3ca-mutated and Pten-deleted prostate hyperplasia and carcinoma. (A) IHC to detect the apoptotic marker Cleaved-Caspase-3 (CC3) in Wt, Pik3ca+/HR and Ptenfl/fl mice at 400 d (scale bar: 50 um). (B) Quantitation of CC3-positive nuclei in Wt, Pik3ca+/HR and Ptenfl/fl prostate epithelium (n = 3, *P <0.05 compared to Wt, or as indicated, one-way ANOVA with Tukey's multiple comparison test, ns = not significant. Error bars: SEM). (C) IHC to detect CK5 and CK8 in Pik3ca+/HR and Ptenfl/fl carcinomas (representative images from 3 prostates per genotype, scale bar: 50 um). (D) Representative IHC images to detect PTEN, mTORC1 signaling components (p-AKT Thr308, p-RPS6 Ser235/236 and p-4E-BP1 Thr37/46) and mTORC2 substrates (p-AKT Ser473 and p-NDRG1 Thr346) in Pik3ca+/HR and Ptenfl/fl hyperplastic lesions (n = 3, scale bar: 50 um). IHC quantitation for (E) p-AKT Thr308, (F) p-RPS6 Ser235/236, (G) p-4E-BP1 Thr37/46, (H) p-AKT Ser473 and (I) p-NDRG1 Thr346 in Pik3ca+/HR and Ptenfl/fl prostate hyperplastic lesions (n = 3, Error bars: SEM, *P < 0.05, unpaired, two-tailed t-test).